Partners
CRUN
The Clinical Research Unit of Nanoro (IRSS-CRUN) was created in 2008 to provide a much-needed Good Clinical Practices (GCP) compliant trial platform for training and research activities. The CRUN’s mission is to provide evidence-based information for the health care of populations living in tropical countries. The team’s scientific interest at the creation in 2008 was mainly malaria research and the team implemented several studies in this topic including the GSK RTS,S phase 3 malaria vaccine candidate trial. However, with the epidemiological transition leading to a decline of malaria global incidence in the last decade, other infectious diseases are becoming of more important public health concern, especially in sub-Saharan Africa. In this context, since the last five years the CRUN has gradually diversified its research portfolio to consider other diseases besides malaria.
We set-up in 2009 a Health and Demographic Surveillance System (HDSS) of about 66,000 people. Since then, a dynamic approach was used engaging local community throughout the process. With a multidisciplinary team, we completed more than 40 research (3 trials on malaria vaccine) projects and published 140 articles in peer review journals in the last ten years.
For more information visit www.crun.bf or contact info [at] crun [dot] bf
The Manhiça Health Research Centre (Centro de Investigação em Saúde de Manhiça, CISM), created in 1996 is a research institution managed by Manhiça Foundation, whose mission is to promote and conduct biomedical research in health priority areas to promote and safeguard the health of the population. CISM has three platforms (demographic, geographic and morbidity surveillance platforms) that are crucial for the development of the center’s research activities. The activities of CISM stand on three pillars: research, training and healthcare.
For more information visit www.manhica.org or contact Sonia Mocumbi, Communication and Institutional Relations Officer via +258 82 289 4441 or sonia [dot] mocumbi [at] manhica [dot] org
The Eberhard Karls Universität Tübingen
The Eberhard Karls Universität Tübingen is one of Europe’s oldest universities, with key strengths in Sciences and Life Sciences. Within the Faculty of Medicine, the Institute of Tropical Medicine (ITM) is an established Centre of Excellence (since 2007). Approximately 25 different courses including lectures, seminars, colloquia, internships and courses for beginners, advanced and post-graduates are offered on a semester basis. ITM is part of the Comprehensive Infectious Disease Center (CIDiC) at the University Hospital Tübingen and a site of the German Center for Infection Research (DZIF). The institute conducts research, teaching and patient care in tropical medicine, human parasitology, and travel medicine. ITM is a leading institution performing clinical trials in infectious diseases, especially antimalarial, interventions and vaccines both at its dedicated Clinical Trials Platform and in collaboration with partner sites in tropical countries around the world.
For more information, visit https://uni-tuebingen.de/en/
GRAS
The Groupe de Recherche Action en Santé (GRAS) is a private institute based in Burkina Faso, operating since 2008 in the field of health research. The scientific staff of GRAS is multi-disciplinary with well proven skills in clinical trials. They carried out, during last decade, more than 25 clinical trials for various infectious diseases (Malaria vaccines, Pneumococcal vaccines, Ebola vaccines, Typhoid fever vaccine, etc.). GRAS is currently a member of several consortia working to develop new treatments or vaccines against these diseases.
For more information, visit www.gras.bf or contact info [at] gras [dot] bf and +22625 35 56 90
IDRC
The Infectious Diseases Research Collaboration (IDRC) is a non-profit research organization. IDRC conducts research in infectious diseases including Malaria, HIV, Tuberculosis and other diseases of public health importance through collaboration and partnership. IDRC's studies have led to over 300 publications and have impacted on the management of infectious diseases in Uganda.
For more information visit http://idrc-uganda.org/ or contact admin [at] idrc-uganda [dot] org
ISGlobal
The Barcelona Institute for Global Health, ISGlobal, is the fruit of an innovative alliance between "la Caixa", academic institutions and government bodies to contribute to the efforts undertaken by the international community to address the challenges in global health.
ISGlobal is a consolidated hub of excellence in research that has grown out of work first started in the world of health care by the Hospital Clínic and the Parc de Salut MAR and in the academic sphere by the University of Barcelona and Pompeu Fabra University. The pivotal mechanism of its work model is the transfer of knowledge generated by scientific research to practice, a task undertaken by the institute’s Education and Policy and Global Development departments.
Its ultimate goal is to help close the gaps in health disparities between and within different regions of the world.
For more information, visit https://www.isglobal.org or contact info [at] isglobal [dot] org
MMV
Medicines for Malaria Venture (MMV) is a leading product development partnership (PDP) in antimalarial drug research in its 20th year. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. Since its foundation, MMV and partners have developed and brought forward eleven new medicines estimated to have saved around 2.2. million lives.
For more information visit www.mmv.org
Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create
transformative treatments in areas of great medical need. In our quest to find new
medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world.
For more information visit www.novartis.com or contact media [dot] relations [at] novartis [dot] com
Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
CERMEL
The Lambaréné Medical Research Center (CERMEL) is a non-profit association. Dedicated to medical research, clinical evaluation of vaccines and drugs. CERMEL specializes in research into treatments for tropical and infectious diseases such as malaria, tuberculosis, HIV / AIDS, intestinal worms, Ebola, etc. To promote the improvement of preventive and curative care for these diseases on the one hand and on the other hand the public health system as a whole in Africa and in Gabon in particular.